

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, DC 20231

ı					ATTORNEY DOCKET NO.	
	09/073,138 05/	05/98	KAWAKAMI		Υ.	2026-4124US3
Γ	- WILLIAM S FEILER MORGAN & FINNEGAN		HM21/1103 ¬		HUFF, S	XAMINER
	345 PARK AVENUE NEW YORK NY 1015	4		l	ART UNIT 1642	PAPER NUMBER
				•	DATE MAILED:	11/03/98

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. 09/073,138

Applicant(s)

Kawakami et al

Examiner

Sheela J. Huff

Group Art Unit 1642



X Responsive to communication(s) filed on Sep 4, 1998	·
☐ This action is FINAL .	
☐ Since this application is in condition for allowance except for for in accordance with the practice under <i>Ex parte Quayle</i> , 1935 (ormal matters, prosecution as to the merits is closed C.D. 11; 453 O.G. 213.
A shortened statutory period for response to this action is set to e is longer, from the mailing date of this communication. Failure to application to become abandoned. (35 U.S.C. § 133). Extension 37 CFR 1.136(a).	respond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	·
Claim(s)	
Claim(s)	
☐ Claims	
Application Papers	
X See the attached Notice of Draftsperson's Patent Drawing R	leview, PTO-948.
☐ The drawing(s) filed on is/are objected	d to by the Examiner.
☐ The proposed drawing correction, filed on	is 🗌 approved 🔲 disapproved.
\square The specification is objected to by the Examiner.	
$\hfill\Box$ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	·
☐ Acknowledgement is made of a claim for foreign priority und	der 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the	ne priority documents have been
received.	
☐ received in Application No. (Series Code/Serial Number	
☐ received in this national stage application from the Int	ernational Bureau (PCT Rule 17.2(a)).
*Certified copies not received:	
Acknowledgement is made of a claim for domestic priority u	inder 35 U.S.C. § 119(e).
Attachment(s)	
Notice of References Cited, PTO-892	
☑ Information Disclosure Statement(s), PTO-1449, Paper No(s ☐ Interview Summary, PTO-413). <u> </u>
☑ Notice of Draftsperson's Patent Drawing Review, PTO-948	
☐ Notice of Informal Patent Application, PTO-152	•
10 Notice to Comply w/ Seq.	Rules
SEE OFFICE ACTION ON THE	EOLOWING PAGES

Art Unit: 1642

DETAILED ACTION

1. Claims 1-28 and 32-38 were cancelled in the transmittal filed on 5/5/98. The Examiner did not see this and sent out the restriction requirement, mailed 7/1/98. This restriction requirement is withdrawn in view of the fact that cancelled claims had been included in the restriction. Claims 29-31 are pending and currently under consideration.

Sequence Listing

2. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is directed to MPEP 2422.05 for procedures for filing sequence listing in continuations.

Information Disclosure Statement

3. The IDS filed 5/5/98 has been considered and an initialed copy of the PTO-1449 is enclosed.

ί

Application/Control Number: 09/073138

Art Unit: 1642

Claim Rejections - 35 USC § 112

4. Claims 29-31 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the use of gp100 and several gp100 peptides (SEQ ID No. 33, 46-49, 34 and 40--see page 96 of specification) to induce tumor regression, does not reasonably provide enablement for peptides having any contiguous amino acid composition therein. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

Applicant's claims read on the use of peptides as small as dipeptides and peptides are large as 660 amino acids to treat melanomas. The examples given in the specification are limited to short peptides consisting of about 10-12 amino acids. Thus, it is clear from applicant's own specification that there are limitations as to what the contiguous sequence of amino acids can be. Inserting these limitations into the specification will overcome this rejection. Absent this limitations, the claims read on thousands and thousands of peptides (peptides ranging in size from dipeptides to peptides having 660 amino acids). Applicant has not demonstrated that any peptides smaller than 10 amino acids or greater than 12 amino acids can have the claimed effect. It is well known in the art of peptide chemistry that altering the size of the peptide leads to changes in conformation, overall polarity, steric hinderance and charge. This would alter the peptides' ability to interact with its appropriate counterpart

Application/Control Number: 09/073138

Art Unit: 1642

and this would clearly disrupt the interaction and thus effect of the peptide. There is no

Page 4

guidance in the specification as to how long or how short the peptide must be in order

for the peptide to retain its ability. Thus, undue experimentation would be required by

one skilled in the art to determine which of the thousands of peptides possess the

ability recited in the claims.

5. Claim 29 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite

for failing to particularly point out and distinctly claim the subject matter which applicant

regards as the invention.

The terminology "effective amount" renders the claim vague and indefinite.

Effective for what???

Conclusion

6. The claims are free from the art of record because the prior art neither teaches

nor suggests full length gp100 or fragments thereof in a pharmaceutical formulation

with a pharmaceutically acceptable carrier.

7. No claim is allowed.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheela J. Huff whose telephone number is (703) 305-

7866. The Examiner can normally be reached on Monday, Wednesday and Friday

from 6:30am to 4:00pm and Tuesday 1:00pm to 5:00pm.

Application/Control Number: 09/073138

Page 5

Art Unit: 1642

If attempts to teach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Paula Hutzell, can be reached on (703)308-4310.

The FAX phone number for the group is (703)308-4242.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [paula.hutzell@uspto.gov].

All Internet e-mail communications will be made of record in the application file.

PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703)308-0196.

Sheela J. Huff October 26, 1998

> Sheela J. Huff Primary Examiner

Sheela J. Huff

Application No.: 09/073138

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's
attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence"
Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822
and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged
and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:
An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

For Patentin software help, call (703) 308-6856